Eagle Pharmaceuticals, Inc.
EGRX · OTC
3/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $366,935 | $378,058 | $664,562 | $627,835 |
| - Cash | $0 | $55,321 | $97,659 | $103,155 |
| + Debt | $0 | $67,789 | $29,820 | $38,217 |
| Enterprise Value | $366,935 | $390,526 | $596,723 | $562,897 |
| Revenue | – | $316,610 | $171,546 | $187,802 |
| % Growth | – | 84.6% | -8.7% | – |
| Gross Profit | – | $221,674 | $129,366 | $142,337 |
| % Margin | – | 70% | 75.4% | 75.8% |
| EBITDA | – | $77,502 | $847 | $30,020 |
| % Margin | – | 24.5% | 0.5% | 16% |
| Net Income | – | $35,642 | -$8,627 | $11,989 |
| % Margin | – | 11.3% | -5% | 6.4% |
| EPS Diluted | – | 2.73 | -0.66 | 0.87 |
| % Growth | – | 513.6% | -175.9% | – |
| Operating Cash Flow | $30,797 | $50,701 | $28,219 | $49,497 |
| Capital Expenditures | $0 | -$178 | -$323 | -$747 |
| Free Cash Flow | $30,797 | $50,523 | $27,896 | $48,750 |